PUMA BIOTECHNOLOGY, INC. | 2013 | FY | 3


The CRO contracts held by the Company as of December 31, 2013, are summarized as follows (in thousands):

 

Indication

   Total
Contract

Amount
Remaining
as of
December 31,
2013
     Months
Remaining
on Contract
 

HER2 Mutation Positive Solid Tumor (5201)

   $ 3,560         32   

HER2 Mutuant Non-Small Cell Lung Cancer (4201)

     5,060         28   

HER2 Overexpressed/Amplified Breast Cancer (Licensor Legacy Clinical Trials)

     18,389         15   

HER2 Plus Metastatic Breast Cancer (1301)

     46,477         43   

Metastatic HER2-Amplified or Triple-Negative Breast Cancer (10-005)

     1,399         36   
  

 

 

    
   $ 74,885      
  

 

 

    



us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock